Health Boards
Quote:
Cosentyx addresses the cornerstone cytokine interleukin-17A (IL-17A) involved in the development and progression of psoriasis, and is the first and only fully human IL-17A inhibitor to show sustained skin clearance rates at 5 years in psoriasis. By working to specifically target and inhibit IL-17A, Cosentyx can more effectively address the underlying cause of the disease. To date, psoriasis treatments targeting other, less direct, pathways have not shown long-term efficacy out to 2.5 years in these hard-to-treat forms.
This is great news.... if I read it well, IL-17A, is the cause of the disease !!!!!
Or am I reading not correctly????
You know, I have always thought the cause is somewhere either located in the genes or in something like stubborn bacteria in your body, where the real problem, Psoriasis is triggered by causes like stress or trauma or otherwise.
IL-17A the cause? I doubt it.
And I think I am reading it wrongly. It says:"Cosentyx can more effectively address the underlying cause of the disease."
It addresses the underlying cause. But what "is" the underlying cause? Apparantly Novartis knows it.
What I think is that IL-17A is blocked, at least that is the purpose of an inhibitor, so the effect is that the expression of the Psoriasis and specifically the arthritis, the inflammations, are prevented. But as far as I know the cause of the Psoriasis is not touched. It is only the expression.